Sugi Predict

Sugi Predict / Targets / CRBN

CRBN

Protein cereblon · Q96SW2 · CRBN on Sugi Atlas →

263,930 patent compounds predicted against CRBN, 143,177 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Avadomide Avadomide (SCHEMBL282749) 1.00 20/20
SCHEMBL283113 SCHEMBL283113 0.74 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL284301) 0.72 20/20
SCHEMBL283120 SCHEMBL283120 0.68 20/20
SCHEMBL286218 SCHEMBL286218 0.66 20/20
SCHEMBL283467 SCHEMBL283467 0.59 20/20
SCHEMBL284416 SCHEMBL284416 0.59 20/20
SCHEMBL328540 SCHEMBL328540 0.56 20/20
Thalidomide Thalidomide (SCHEMBL7581) 1.00 19/20
Thalidomide Thalidomide (SCHEMBL41641) 1.00 19/20
SCHEMBL282492 SCHEMBL282492 0.79 19/20
SCHEMBL283184 SCHEMBL283184 0.79 19/20
SCHEMBL283314 SCHEMBL283314 0.79 19/20
SCHEMBL283241 SCHEMBL283241 0.75 19/20
SCHEMBL282792 SCHEMBL282792 0.74 19/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL284302) 0.74 19/20
SCHEMBL282871 SCHEMBL282871 0.70 19/20
SCHEMBL282494 SCHEMBL282494 0.67 19/20
SCHEMBL282263 SCHEMBL282263 0.64 19/20
SCHEMBL283372 SCHEMBL283372 0.64 19/20

Clinical trials — most relevant to CRBN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib PHASE3COMPLETED
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma PHASE1/PHASE2WITHDRAWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) PHASE2ACTIVE_NOT_RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas PHASE1/PHASE2COMPLETED
Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR) PHASE2COMPLETED
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients PHASE1COMPLETED
A Window of Opportunity Study of Black Raspberry for Patients With HNSCC EARLY_PHASE1WITHDRAWN
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy EARLY_PHASE1RECRUITING
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421 nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Characterization of Angelman Syndrome nanCOMPLETED
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN
Angelman Syndrome Natural History Study nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma nanCOMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping nanUNKNOWN
Serum Talin-1 and Cripto-1 in Colorectal Cancer nanNOT_YET_RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Biomarkers of CASH nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CRBN binder may also engage these)

ProteinNameSimilarity
Q0P564 — 1.000 Q0P564 →
Q5R6Y2 — 1.000 Q5R6Y2 →
P0CF65 — 1.000 P0CF65 →
Q56AP7 — 1.000 Q56AP7 →
Q8C7D2 — 0.997 Q8C7D2 →
Q68EH9 — 0.994 Q68EH9 →
Q640S2 — 0.993 Q640S2 →
Q86VS3 — 0.986 Q86VS3 →
Q9D2K4 — 0.985 Q9D2K4 →
Q8C5W4 — 0.985 Q8C5W4 →
A6H8I2 — 0.984 A6H8I2 →
Q8C0M0 — 0.984 Q8C0M0 →
Q5R7E5 — 0.984 Q5R7E5 →
Q6DCF6 — 0.984 Q6DCF6 →
Q008S8 — 0.984 Q008S8 →
Q69LX2 — 0.983 Q69LX2 →
O14830 — 0.983 O14830 →
A2VDP2 — 0.983 A2VDP2 →
Q8VDY4 — 0.983 Q8VDY4 →
Q09YK6 — 0.983 Q09YK6 →
B3M1E1 — 0.983 B3M1E1 →
Q5ZLG9 — 0.983 Q5ZLG9 →
Q07E17 — 0.982 Q07E17 →
Q2IBB1 — 0.982 Q2IBB1 →
Q7T2Z5 — 0.982 Q7T2Z5 →
F1QLY4 — 0.982 F1QLY4 →
Q8BMJ7 — 0.982 Q8BMJ7 →
Q6DFC6 — 0.982 Q6DFC6 →
Q2QLG0 — 0.982 Q2QLG0 →
Q566H4 — 0.982 Q566H4 →